Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Apple Turns 50: From Garage Startup to AI Crossroads 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
VALENCIA, Calif., Jan. 05, 2017 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, will present today at the 35th Annual J.P. Morgan Healthcare Conference at 10:00 AM (PST) at the Westin St. Francis Hotel in San Francisco, California.
Presenting from the Company will be its Chief Executive Officer, Matthew J. Pfeffer.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP Finance 661-775-5300 [email protected]
